| Identification | Back Directory | [Name]
GSK-CXCR2 | [CAS]
211096-49-0 | [Synonyms]
GSK-CXCR2
SB 265610
SB265610 >=98% (HPLC)
N-(2-Bromophenyl)-N'-(7-cyano-1H-benzotriazol-4-yl)urea
Urea, N-(2-bromophenyl)-N'-(4-cyano-1H-benzotriazol-7-yl)-
1-(2-Bromophenyl)-3-(4-cyano-1H-benzo[d] [1,2,3]triazol-7-yl)urea | [Molecular Formula]
C14H9BrN6O | [MDL Number]
MFCD09971124 | [MOL File]
211096-49-0.mol | [Molecular Weight]
357.16 |
| Hazard Information | Back Directory | [Uses]
SB 265610 is an anti-tumor pharmaceutical developed to act as an antagonist to cysteine-amino acid-cysteine (CXC) chemokines receptor 2 antagonist. | [Biological Activity]
Potent CXCR2 antagonist that inhibits CINC-1-mediated but not C5a-mediated Ca 2+ mobilization (IC 50 values are 3.4 and 6800 nM respectively). Inhibits CINC-induced chemotaxis and attenuates neutrophil accumulation in inflammatory lung injury in vivo . | [Biochem/physiol Actions]
SB265610 is a potent and selective CXCR2 chemokine receptor antagonist. It has a Kd = 2.5 nM. | [storage]
Store at RT |
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
|